Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome — Commercial launch of DAYBUE offers Rett syndrome community the first and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000… Read More
18th Rett Classic Registration
Leave a Comment
Last Updated: 06/06/2023 by Steve
Registration for the 18th Rett Classic closes Sunday, May 28, 2023.
2023 Hope Fund Grant Winners
Leave a Comment
Last Updated: 07/26/2023 by admin
The Ontario Rett Syndrome Association (O.R.S.A.) Board of Directors has unanimously approved the funding of two research grant totaling $150,000 from The Hope Fund for 2023. The Hope Fund has funded over $828,000 in Canadian research to date…. Read More
DayBue Announcement
Leave a Comment
Last Updated: 07/26/2023 by admin
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome — Commercial launch of DAYBUE offers Rett syndrome community the first and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000… Read More